NCT01065623 (Clinical Trial/ BAY79-4620)

Study Title
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY79-4620 Given Every 2 Weeks to Patients With Advanced Solid Tumors (NCT01065623)

Trial Description
Clinical study to determine safety, tolerability, to measure how the drug is metabolized by the body and to determine the maximum tolerated dose of BAY79-4620 given every 2 weeks to patients with advanced solid tumors. This trial is sponsored by Bayer. [1]

Study Data

  • Condition: Neoplasms
  • Interventions:
    • Drugs used in this trial
      • BAY79-4620
  • Phase: I
  • Enrollment: 2
  • Start: April 2010
  • Completion: August 2010
  • Last verified: September 2014

Study Schematic

 Screen Shot 2016-07-06 at 4.31.25 PM


Click here to Return to Drug map

Last Editorial review: July 7, 2016
Information based on (NIH/NCI) and other sources.